Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Oct;62(10):1457-1460.
doi: 10.2967/jnumed.120.258434. Epub 2021 Feb 26.

Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study

Minseok Suh  1   2 , Hyung-Jun Im  2   3 , Hyun Gee Ryoo  1   2 , Keon Wook Kang  1 , Jae Min Jeong  1 , Sneha Prakash  4 , Sanjana Ballal  4 , Madhav P Yadav  4 , Chandrasekhar Bal  4 , Chang Wook Jeong  5 , Cheol Kwak  5 , Gi Jeong Cheon  6   7   8
Affiliations
Comparative Study

Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study

Minseok Suh et al. J Nucl Med. 2021 Oct.

Abstract

68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)-targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patients with prostate cancer. Methods: Eleven patients with metastatic prostate cancer were prospectively recruited. The quantitative tracer uptake was determined in normal organs and in primary and metastatic lesions. Results:68Ga-NGUL showed significantly lower normal-organ uptake and rapid urinary clearance. The number and sites of detected PSMA-positive primary and metastatic lesions were identical, and no significant quantitative uptake difference was observed. 68Ga-NGUL showed a relatively lower tumor-to-background ratio than 68Ga-PSMA-11. Conclusion: In a head-to-head comparison with 68Ga-PSMA-11, 68Ga-NGUL showed lower uptake in normal organs and similar performance in detecting PSMA-avid primary and metastatic lesions. 68Ga-NGUL could be a valuable option for PSMA imaging.

Keywords: 68Ga-NGUL; 68Ga-PSMA-11; biodistribution; prostate-specific membrane antigen.

PubMed Disclaimer

Figures

None
Graphical abstract
FIGURE 1.
FIGURE 1.
(A) SUVmean of normal organs for 68Ga-PSMA-11 and 68Ga-NGUL. Median with interquartile range as error bar is plotted on bar chart. Wilcoxon signed-rank test for paired data was used for statistical comparison. (B) Representative image showing normal-organ distribution of 68Ga-PSMA-11 and 68Ga-NGUL. B = bladder; K = kidney; L = liver; S = spleen; SG = salivary glands; SUVbw = SUV body weight.
FIGURE 2.
FIGURE 2.
Time–activity curve of both 68Ga-PSMA-11 and 68Ga-NGUL derived from bladder region of interest.
FIGURE 3.
FIGURE 3.
(A) SUVmax of primary tumor, lymph node, and bone metastases for 68Ga-PSMA-11 and 68Ga-NGUL. (B) Tumor-to-background ratio of primary tumor, lymph node, and bone metastases for 68Ga-PSMA-11 and 68Ga-NGUL. Median with interquartile range as error bar is plotted on bar chart. Wilcoxon signed-rank test for paired data was used for statistical comparison.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Iravani A, Violet J, Azad A, Hofman MS. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer Prostatic Dis. 2020;23:38–52. - PubMed
    1. Siva S, Udovicich C, Tran B, Zargar H, Murphy DG, Hofman MS. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. Nat Rev Urol. 2020;17:107–118. - PubMed
    1. Eder M, Schafer M, Bauder-Wust U, et al. . 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–697. - PubMed
    1. Ceci F, Uprimny C, Nilica B, et al. . 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284–1294. - PubMed
    1. Fendler WP, Eiber M, Beheshti M, et al. . 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014–1024. - PubMed

Publication types